• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Publisher Correction: A clonal expression biomarker associates with lung cancer mortality.

作者信息

Biswas Dhruva, Birkbak Nicolai J, Rosenthal Rachel, Hiley Crispin T, Lim Emilia L, Papp Krisztian, Boeing Stefan, Krzystanek Marcin, Djureinovic Dijana, La Fleur Linnea, Greco Maria, Döme Balázs, Fillinger János, Brunnström Hans, Wu Yin, Moore David A, Skrzypski Marcin, Abbosh Christopher, Litchfield Kevin, Al Bakir Maise, Watkins Thomas B K, Veeriah Selvaraju, Wilson Gareth A, Jamal-Hanjani Mariam, Moldvay Judit, Botling Johan, Chinnaiyan Arul M, Micke Patrick, Hackshaw Allan, Bartek Jiri, Csabai Istvan, Szallasi Zoltan, Herrero Javier, McGranahan Nicholas, Swanton Charles

机构信息

Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, Paul O'Gorman Building, London, UK.

Bill Lyons Informatics Centre, University College London Cancer Institute, Paul O'Gorman Building, London, UK.

出版信息

Nat Med. 2020 Jul;26(7):1148. doi: 10.1038/s41591-020-0899-z.

DOI:10.1038/s41591-020-0899-z
PMID:32494065
Abstract

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

摘要

相似文献

1
Publisher Correction: A clonal expression biomarker associates with lung cancer mortality.
Nat Med. 2020 Jul;26(7):1148. doi: 10.1038/s41591-020-0899-z.
2
Publisher Correction: The National Lung Matrix Trial of personalized therapy in lung cancer.出版商更正：肺癌个性化治疗的国家肺部基质试验。
Nature. 2020 Sep;585(7826):E21. doi: 10.1038/s41586-020-2656-3.
3
Publisher Correction: The Technome - A Predictive Internal Calibration Approach for Quantitative Imaging Biomarker Research.出版商更正：技术组——定量成像生物标志物研究的一种预测性内部校准方法。
Sci Rep. 2020 Jul 7;10(1):11442. doi: 10.1038/s41598-020-68534-w.
4
Publisher Correction: Soluble LRP1 is an independent biomarker of epicardial fat volume in patients with type 1 diabetes mellitus.出版商更正：可溶性低密度脂蛋白受体相关蛋白1是1型糖尿病患者心外膜脂肪体积的独立生物标志物。
Sci Rep. 2019 Nov 8;9(1):16715. doi: 10.1038/s41598-019-53407-8.
5
Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial.
Nat Med. 2020 Jun;26(6):983. doi: 10.1038/s41591-020-0923-3.
6
Publisher Correction: In vivo imaging of mitochondrial membrane potential in non-small-cell lung cancer.
Nature. 2020 Jan;577(7791):E7. doi: 10.1038/s41586-019-1890-z.
7
Publisher Correction: Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer.出版商更正：T细胞受体库的空间异质性反映了肺癌中的突变格局。
Nat Med. 2020 Jul;26(7):1148. doi: 10.1038/s41591-020-0866-8.
8
Publisher Correction: A mass spectrometry-based proteome map of drug action in lung cancer cell lines.出版商更正：基于质谱的肺癌细胞系药物作用蛋白质组图谱。
Nat Chem Biol. 2020 Oct;16(10):1149. doi: 10.1038/s41589-020-0643-5.
9
Publisher Correction: Exuberant fibroblast activity compromises lung function via ADAMTS4.出版商更正：旺盛的成纤维细胞活性通过ADAMTS4损害肺功能。
Nature. 2020 Dec;588(7836):E5. doi: 10.1038/s41586-020-2987-0.
10
Publisher Correction: Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer.出版商更正：CRISPR 编辑的 T 细胞在难治性非小细胞肺癌患者中的安全性和可行性。
Nat Med. 2020 Jul;26(7):1149. doi: 10.1038/s41591-020-0973-6.